First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
Centre aims to train surgeons and other healthcare professionals from India and Southeast Asia in robotic-assisted surgery
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Combating the prevalent stigma against TB in the society, India has been committed to providing, enabling and patient-centric support to all, individuals suffering from TB
Lupin actively contributes to alleviating the burden of COPD for patients across the nation
This is the 166th ANDA out of Eugia Pharma Speciality Group facilities
India is committed to eliminating Lymphatic Filariasis by 2027, three years ahead of the global target through mission mode, multi partner, multi sector targeted drive
AushadhAI is purposefully designed to deliver significant advantages to the pharmaceutical supply chain's key constituents
The product is being launched in August 2023
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
